Bicarbonate Administration in CKD
| Status: | Recruiting |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 21 - 80 |
| Updated: | 7/28/2018 |
| Start Date: | January 15, 2017 |
| End Date: | September 2021 |
| Contact: | Jessica Kendrick, MD |
| Email: | Jessica.Kendrick@ucdenver.edu |
| Phone: | 303-602-5012 |
Low serum bicarbonate levels, even within the normal laboratory range, are strongly
associated with increased risks of hypertension, endothelial dysfunction, cardiovascular
disease and death. The current proposal will investigate whether bicarbonate administration
in patients with chronic kidney disease (CKD) will improve the health and function of
arteries and reduce the size of the left ventricle of the heart. Overall, the proposed
research will provide important new scientific evidence upon which physicians can base
recommendations to patients with CKD to decrease the risk of developing cardiovascular
diseases.
associated with increased risks of hypertension, endothelial dysfunction, cardiovascular
disease and death. The current proposal will investigate whether bicarbonate administration
in patients with chronic kidney disease (CKD) will improve the health and function of
arteries and reduce the size of the left ventricle of the heart. Overall, the proposed
research will provide important new scientific evidence upon which physicians can base
recommendations to patients with CKD to decrease the risk of developing cardiovascular
diseases.
Inclusion Criteria:
- Age ≥ 21 years
- Serum bicarbonate 22-25 mEq/L on 2 separate measurements (at least 1 day apart)
- CKD stage 3B or 4 at time of screening (eGFR 15-44 ml/min/1.73m2)
- Blood pressure <130/80 mm Hg prior to randomization
- BMI < 40 kg/m2 (FMD measurements can be inaccurate in severely obese patients).
- Able to provide consent
- Stable anti-hypertensive regimen for at least one month prior to randomization
- Not taking medications that interact with agents administered during experimental
sessions (e.g. sildenafil interacts with nitroglycerin).
Exclusion Criteria:
- Use of chronic daily oral alkali within the last 3 months (including sodium
bicarbonate, calcium carbonate or baking soda)
- Uncontrolled hypertension
- Serum potassium < 3.3 or ≥ 5.5 mEq/L at screening
- New York Heart Association Class 3 or 4 heart failure symptoms, known EF ≤30%, or
hospital admission for heart failure within the past 3 months
- Factors judged to limit adherence to interventions
- Anticipated initiation of dialysis or kidney transplantation within 12 months
- Current participation in another research study
- Pregnancy or planning to become pregnant or currently breastfeeding
- Chronic use of supplemental oxygen
- Use of immunosuppression in past 3 months
- Metal implant or implanted electrical device (patient will be unable to get MRI)
We found this trial at
1
site
13001 E. 17th Pl
Aurora, Colorado 80045
Aurora, Colorado 80045
303-724-5000
Principal Investigator: Jessica Kendrick, MD
Phone: 303-602-5012
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
Click here to add this to my saved trials
